FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
DECEMBER 2017
MEDICAL ONCOLOGY
PAPER II

POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.
Time 3 hours MED.ONCO./D/17/17/II
Max. Marks 100
Important instructions:
• Attempt all questions in order.
• Each question carries 10 marks.
• Read the question carefully and answer to the point neatly and legibly.
• Do not leave any blank pages between two answers.
• Indicate the question number correctly for the answer in the margin space.
• Answer all the parts of a single question together.
• Start the answer to a question on a fresh page or leave adequate space between two
answers.
• Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
1. Describe about breast cancer under following headings.
a. Her 2 neu gene testing: Immunohistochemistry versus
FISH.
b. Use of Her-2 neu targeted therapy in neo-adjuvant,
adjuvant and metastatic setting.
3+7
2. a. List the investigation in a suspected case of chronic
myeloproliforative disease (CMPD)
b. Molecular biology of Ph negative CMPD
c. Ruxolitinib: Indications and side effects

3. a. Lugano staging of non Hodgkin's lymphoma
b. Describe criteria for response assessment in
lymphoma
4+6
4. a. Pathology of gastric carcinoma
b. Treatment both chemotherapy and targeted for
unresectable gastric carcinoma
4+6
5. a. List various cytotoxic agents associated with severe
emesis.
b. Prevention and treatment of chemotherapy induced
nausea and vomiting with various agents.
c. Explain their mechanism of action and side effects.

6. a. Pathology of medulloblastoma.
b. Molecular classification of medulloblastoma
c. Staging of medulloblastoma and salient investigations
for its staging.


7. a. Role of check point inhibitors in non small cell lung
cancer (NSCLS)
b. Algorithm for first time treatment of metastatic NSCLS
c. Role of ceritinib and alectinib in NSCLC with brain
metastasis

8. a. Pathology and staging of prostate cancer.
b. What is androgen resistant prostate cancer?
c. Chemotherapy indications in prostate cancer with
'supporting indications'.

9. a. Pathology of Rhabdomyosarcoma.
b. Cytogenetic/ Translocation studies in sarcoma: mention
tumours where it is useful in diagnosis
c. Huvos grading in osteosarcoma

10. a. Grading of pancreatic neuro-endocrine tumours.
b. Utility of nuclear medicine for diagnosis and treatment
of neuroendocrine tumour.
c. Chemotherapy of neuroendocrine tumor.